Principles of Drug Discovery and Development MCQs With Answer is a focused resource designed for M.Pharm students preparing for exams and professional practice in product development and technology transfer. This set of multiple-choice questions covers core topics such as target identification, lead discovery and optimization, ADME/Tox, preclinical and clinical development stages, regulatory filings (IND/NDA), formulation and CMC considerations, and translational strategies to de-risk candidates. Questions emphasize mechanistic understanding, decision points in development, and practical aspects of technology transfer. Each MCQ includes concise options and a clear answer to help reinforce learning, guide revision, and build competence for real-world pharmaceutical development tasks.
Q1. Which early-stage activity primarily focuses on demonstrating that a biological molecule or pathway contributes to disease and is amenable to therapeutic modulation?
- Lead optimization
- Target identification and validation
- Clinical trial design
- Formulation development
Correct Answer: Target identification and validation
Q2. High-throughput screening (HTS) in lead discovery is mainly used to:
- Assess human pharmacokinetics
- Generate large numbers of chemical hits against a target
- Perform toxicology in two species
- Develop GMP manufacturing processes
Correct Answer: Generate large numbers of chemical hits against a target
Q3. During lead optimization, which property is least likely to be directly optimized through medicinal chemistry modifications?
- Potency at the biological target
- Solubility and permeability
- Intellectual property landscape
- Metabolic stability (intrinsic clearance)
Correct Answer: Intellectual property landscape
Q4. Which in vitro/in silico approach is most commonly used to predict potential drug–drug interactions mediated by cytochrome P450 enzymes?
- hERG channel binding assay
- Microsomal stability assay and CYP inhibition modeling
- In vivo rodent toxicology
- Solubility-pH profiling
Correct Answer: Microsomal stability assay and CYP inhibition modeling
Q5. The IND (Investigational New Drug) application primarily serves to:
- Obtain marketing approval to sell the drug
- Request permission to begin human clinical trials
- Register a manufacturing site for GMP inspection
- Secure patent protection for the molecule
Correct Answer: Request permission to begin human clinical trials
Q6. Which phase of clinical trials is chiefly designed to assess initial safety, tolerability, and pharmacokinetics in humans?
- Phase I
- Phase II
- Phase III
- Phase IV
Correct Answer: Phase I
Q7. In ADME characterization, which parameter best describes the fraction of an oral dose that reaches systemic circulation unchanged?
- Clearance (CL)
- Half-life (t1/2)
- Absolute bioavailability (F)
- Volume of distribution (Vd)
Correct Answer: Absolute bioavailability (F)
Q8. Which regulatory submission is typically required to obtain marketing approval in the United States after successful clinical trials?
- IND (Investigational New Drug)
- ANDA (Abbreviated New Drug Application)
- NDA (New Drug Application)
- Module V dossier
Correct Answer: NDA (New Drug Application)
Q9. Which GLP/GMP-related activity most directly supports technology transfer of an API process to a production site?
- Conducting investigator-initiated clinical trials
- Preparing detailed process qualification (PQ) and validation protocols
- Performing initial target identification assays
- Designing nonclinical disease models
Correct Answer: Preparing detailed process qualification (PQ) and validation protocols
Q10. Structure-based drug design primarily relies on:
- Large-scale animal studies to screen compounds
- Three-dimensional structural information of the target protein
- High-dose toxicity endpoints in rodents
- Empirical formulation screening
Correct Answer: Three-dimensional structural information of the target protein
Q11. Which strategy is most commonly used to reduce the risk of late-stage clinical failure due to unforeseen toxicity?
- Rely solely on in vitro assays
- Implement translational biomarkers and predictive preclinical models
- Skip Phase II and go directly to Phase III
- Increase clinical dose without additional preclinical data
Correct Answer: Implement translational biomarkers and predictive preclinical models
Q12. In formulation development for oral small molecules, a common tactic to improve bioavailability of a poorly soluble compound is to:
- Switch immediately to intravenous administration
- Develop a salt form or solid dispersion to enhance solubility
- Increase tablet size to include more excipient
- Use only aqueous solutions for dosing
Correct Answer: Develop a salt form or solid dispersion to enhance solubility
Q13. Which preclinical toxicology study is generally required by regulators before first-in-human dosing?
- Long-term carcinogenicity studies in rodents
- Acute and repeat-dose toxicity studies in two species including one non-rodent
- Phase IV post-marketing surveillance
- Bioequivalence studies
Correct Answer: Acute and repeat-dose toxicity studies in two species including one non-rodent
Q14. Repurposing an approved drug for a new indication is attractive because it typically:
- Requires completely new CMC development
- Has unknown human safety profile
- Can shorten development time and reduce safety risk
- Always avoids regulatory submission
Correct Answer: Can shorten development time and reduce safety risk
Q15. Which analytical consideration is crucial in CMC documentation to ensure consistent product quality during scale-up?
- Absence of any stability data
- Robust, validated assays for identity, purity, potency, and impurities
- Only relying on theoretical yield estimates
- Using non-qualified raw materials without supplier documentation
Correct Answer: Robust, validated assays for identity, purity, potency, and impurities
Q16. Pharmacokinetic/pharmacodynamic (PK/PD) modeling during development is most useful for:
- Replacing all clinical trials
- Selecting optimal dose and dosing regimen for clinical studies
- Determining nonclinical toxicology endpoints
- Designing manufacturing plant layout
Correct Answer: Selecting optimal dose and dosing regimen for clinical studies
Q17. Which approach is commonly used to protect a new chemical entity’s intellectual property during early development?
- Publishing all experimental details immediately
- Filing a priority patent application covering composition and use
- Sharing the molecule openly with competitors
- Omitting any patenting efforts until after Phase III
Correct Answer: Filing a priority patent application covering composition and use
Q18. In the context of biologics development, a critical early challenge distinct from small molecules is:
- Defining a simple small-molecule synthetic route
- Cell line development and control of product heterogeneity
- Using fixed-dose oral tablets
- Avoiding any immunogenicity testing
Correct Answer: Cell line development and control of product heterogeneity
Q19. Which of the following best describes a “first-in-class” drug candidate?
- An improved formulation of an existing marketed drug
- A compound that targets a mechanism not previously exploited by approved therapies
- A generic version of a small molecule
- A biosimilar to an existing biologic
Correct Answer: A compound that targets a mechanism not previously exploited by approved therapies
Q20. During technology transfer, the receiving manufacturing site should primarily be evaluated for:
- Ability to publish scientific papers
- Compatibility of equipment, trained personnel, and quality systems to reproduce the process
- Proximity to competitor facilities
- Availability of animal housing for GLP studies
Correct Answer: Compatibility of equipment, trained personnel, and quality systems to reproduce the process
